Clinical Neuropharmacology最新文献_第5页

Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression. Abelson 酪氨酸激酶抑制剂在帕金森病和路易体痴呆症中的应用：系统综述、元分析和元回归。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-23 DOI: 10.1097/WNF.0000000000000597

Giovanni Gosch Berton, Amanda Cyntia Lima Fonseca Rodrigues, Rafael Dos Santos Borges, Nicole Rodrigues Cardoso, Thiago Abrahão de Oliveira, Marcos Vinícius Oliveira Marques

{"title":"Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression.","authors":"Giovanni Gosch Berton, Amanda Cyntia Lima Fonseca Rodrigues, Rafael Dos Santos Borges, Nicole Rodrigues Cardoso, Thiago Abrahão de Oliveira, Marcos Vinícius Oliveira Marques","doi":"10.1097/WNF.0000000000000597","DOIUrl":"10.1097/WNF.0000000000000597","url":null,"abstract":"Background: Alpha-synucleinopathies are incurable neurodegenerative diseases. Abelson tyrosine kinase inhibitors (Abl TKIs) may be disease-modifying therapies. This systematic review, meta-analysis, and meta-regression evaluated the use of Abl TKIs in their treatment.Methods: We searched PubMed, Embase, and Cochrane databases for trials using Abl TKIs in patients with Parkinson's disease and Lewy body dementia published until July 2023. The outcome was the change in the MDS-UPDRS-III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale III). DerSimonian-Laird random-effects model was used to calculate the pooled effect estimates. Leave-one-out forest plots were used for the sensitivity analysis, and meta-regression (restricted maximum likelihood) was performed.Results: Five studies (197 patients) were included. Nilotinib 300 mg had an effect size of -1.154 (95% confidence interval [CI], -3.000 to 0.692). Nilotinib 150 mg and bosutinib 100 mg versus placebo yielded 0.82 (95% CI, -3.76 to 5.41). Sensitivity analysis showed that 1 trial changed the significance of the nilotinib 300 mg single-arm analysis (MD = -1.723; 95% CI, -2.178 to -1.268). Meta-regression revealed that lower age (EC = -0.9103, SE = 0.2286, P < 0.0001) and higher baseline MDS-UPDRS-III scores (EC = 0.1210, SE = 0.0168, P < 0.0001) could explain the inefficacy of nilotinib 300 mg.Conclusions: Nilotinib (300 mg) proved effective postsensitivity analysis, unlike lower doses and bosutinib in Parkinson's disease/Lewy body dementia. Abl TKIs showed reduced efficacy in younger, more impaired patients, indicating the need for further testing with higher-potency drugs in patients who have diseases that are in the early stage but with a later onset.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study. 多发性硬化症膀胱过度活动症患者使用索利那新治疗失败后，米拉贝琼附加疗法的有效性和安全性：一项试点研究

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-15 DOI: 10.1097/WNF.0000000000000596

Senem Ertugrul Mut, Ferda Selcuk, Sıla Usar İncirli, Sedef Delibas

{"title":"Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study.","authors":"Senem Ertugrul Mut, Ferda Selcuk, Sıla Usar İncirli, Sedef Delibas","doi":"10.1097/WNF.0000000000000596","DOIUrl":"10.1097/WNF.0000000000000596","url":null,"abstract":"Objectives: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative progressive disease of central nervous system that mostly affects young adults. (1) Because of involvement of spinal cord and brain, lower urinary dysfunction symptoms are commonly encountered. MS patients mostly show overactive bladder symptoms like urgency, frequent daytime urination, and urgency incontinence. Among MS patients, antimuscarinic therapy is the first-line treatment with overactive bladder symptoms as well as in general population yet 30% of the patients show insufficient improvement or intolerance to the treatment (2). In our study, our aim is to evaluate the efficacy and safety of mirabegron add-on treatment in MS patients after inadequate response to antimuscarinic monotherapy.Methods: University of Kyrenia and Dr Burhan Nalbantoglu State hospital's databases were screened for the study. Seventy patients who were residents diagnosed with MS according to McDonald criteria were questioned. Among these patients, a total of 22 of them were included in the study. Inclusion criteria was at least 3 years of MS diagnosis, score of <6 at Expanded Disability Status Scale, and a score of ≥3 at Overactive Bladder Symptom Score Scale.Results: Among selected patients, 10 mg solifenacin treatment was daily started and followed for 4 weeks. Mirabegron add-on treatment was initiated to the 11 patient who had inadequate improvement in overactive bladder symptom score. After mirabegron add-on treatment among 11 patient, there was a sufficient improvement in overactive bladder symptom score (P < 0.008).Conclusions: In our study, we have found that antimuscarinic and mirabegron combination causes improved efficacy for overactive bladder in MS population.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions. 氯胺酮治疗对自闭症和类自闭症患者社交退缩的影响

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000591

Megan Ralston, Alim Osman, Pavan Suryadevara, Elissa Cleland

{"title":"Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions.","authors":"Megan Ralston, Alim Osman, Pavan Suryadevara, Elissa Cleland","doi":"10.1097/WNF.0000000000000591","DOIUrl":"10.1097/WNF.0000000000000591","url":null,"abstract":"Objective: Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions.Methods: A comprehensive search of PubMed and Web of Science was conducted to identify literature involving the use of ketamine to treat symptoms of autism and social withdrawal. Patients with comorbid disorders were also included.Results: Two original studies were found, showing mixed results on the use of ketamine for ASD. The use of esketamine found no statistically significant results, whereas the use of intravenous ketamine was shown to alleviate symptoms of social withdrawal especially in the short term. Neither study reported a significant amount of serious adverse events. Five case reports were also included, showing decreased depressive symptoms and evidence of increased social condition.Conclusions: Research on the use of ketamine for ASD and ASD-related conditions is limited. Evidence of improved social condition exists, but further studies should be conducted to increase sample power and test various doses and methods of administration.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"97-100"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder. ZO-1血清水平作为精神障碍的潜在生物标记物

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000590

Pinar Aydogan Avşar, Merve Akkuş

{"title":"ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder.","authors":"Pinar Aydogan Avşar, Merve Akkuş","doi":"10.1097/WNF.0000000000000590","DOIUrl":"10.1097/WNF.0000000000000590","url":null,"abstract":"Objective: There are limited studies in the literature on the relationship between intestinal and blood-brain barrier permeability and the etiology of schizophrenia. We hypothesized that the difference in serum ZO-1 levels in patients with schizophrenia may affect the severity of the disease. The aim of this study was to investigate the role of changes in serum ZO-1 concentrations in the etiopathogenesis of patients with schizophrenia.Methods: A total of 46 patients, 34 with schizophrenia, 12 with a first psychotic attack, and 37 healthy controls, were included in the study. Symptom severity was determined by applying the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Serum ZO-1 levels were measured from venous blood samples.Results: Serum ZO-1 levels were higher in patients with psychotic disorder compared to healthy controls. There was no statistically significant difference between the groups in the first psychotic attack group and the schizophrenia patients. There was a statistically significant positive correlation between serum ZO-1 levels and Positive and Negative Syndrome Scale positive symptom score.Conclusions: These findings regarding ZO-1 levels suggest that dysregulation of the blood-brain barrier in psychotic disorder may play a role in the etiology of the disorder.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"67-71"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterizing Vitamin B12 Deficiency in Neurology Outpatients: A Retrospective Observational Study. 神经科门诊患者维生素 B12 缺乏症的特征：回顾性观察研究

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000593

Li Zhou, Xue Bai, Bowen Wu, Yongjun Tan, Mengxia Li, Qin Yang

{"title":"Characterizing Vitamin B12 Deficiency in Neurology Outpatients: A Retrospective Observational Study.","authors":"Li Zhou, Xue Bai, Bowen Wu, Yongjun Tan, Mengxia Li, Qin Yang","doi":"10.1097/WNF.0000000000000593","DOIUrl":"10.1097/WNF.0000000000000593","url":null,"abstract":"Objectives: Clinical manifestations of vitamin B12 deficiency are varied and may result in missed or delayed diagnosis. This investigation explores the diverse clinical manifestations and demographic characteristics of vitamin B12 deficiency in neurology outpatients, aiming to enhance timely diagnosis and outcomes.Methods: The severity of vitamin B12 deficiency was classified as absolute (≤150 pg/mL) or borderline deficiency (150-300 pg/mL). We conducted a retrospective analysis of 165 outpatients with vitamin B12 deficiency at the department of neurology between May 2020 and May 2021.Result: Absolute vitamin B12 deficiency was found in 23.0% of the patients. The most common age range was 50-60 years, the most common cause was vegetarianism, and the most common symptom was headache. Epileptiform symptoms were more likely to occur in younger patients (<20 years old) with vitamin B12 deficiency, whereas psychiatric symptoms were more likely to occur in older patients (>70 years old). Vegetarians, salivation, and nonmegaloblastic anemia were more obvious in patients with absolute vitamin B12 deficiency, whereas headaches often showed borderline B12 deficiency.Conclusions: The clinical characteristics of vitamin B12 deficiency are complex and nonspecific. The diagnosis should be based on multiple factors.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"87-96"},"PeriodicalIF":1.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retinal Tear Following Low-Frequency Repetitive Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder. 低频重复经颅磁刺激治疗强迫症后的视网膜撕裂。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000589

Beyazit Garip, Burcu Buzkan, Suleyman Demir

{"title":"Retinal Tear Following Low-Frequency Repetitive Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder.","authors":"Beyazit Garip, Burcu Buzkan, Suleyman Demir","doi":"10.1097/WNF.0000000000000589","DOIUrl":"10.1097/WNF.0000000000000589","url":null,"abstract":"Objectives: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive form of brain stimulation that uses magnetic pulses to stimulate specific brain regions. Retina is being investigated whether the retina, which is also known as the brain's window to the outside world, is affected by the treatment.Methods: Magventure X100 device was used for the procedure. The bilateral supplementary motor area was targeted. Procedure protocol: power: 47%, repetitive rate (frequency): 1 Hz, pulses in train duration: 300, intertrain interval (waiting time): 120 seconds, number of trains: 4, total pulses: 1200. Twenty sessions of rTMS were planned for the patient. The patient was informed about the procedure, and her consent was obtained.Results: The Yale-Brown Obsessive-Compulsive Disorder Scale (YBOCS) score before the first session was 31, and the Brown Assessment Beliefs Scale (BABS) score was 5. The patient's YBOCS score after the 15th session was 14, and the BABS score was 0. After the implementation of the 15th session of the patient's treatment, retinal detachment developed in the right eye, and the treatment was terminated. As a result of the eye examination of the patient, it was determined that there was 1 horseshoe rupture and 2 hole-shaped ruptures in the lower half of the left eye.Conclusions: Patients at risk for retinal detachment may require specialized treatment and close monitoring to prevent the condition from worsening. It is important to consult with an ophthalmologist for patients at risk for retinal detachment before TMS application.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"101-103"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation of Serum High-Sensitivity C-Reactive Protein, Homocysteine, and Macrophage Migration Inhibitory Factor Levels With Symptom Severity and Cognitive Function in Patients With Schizophrenia. 精神分裂症患者血清高敏 C-反应蛋白、同型半胱氨酸和巨噬细胞迁移抑制因子水平与症状严重程度和认知功能的相关性。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000594

Saizheng Weng, Rongyan Zheng, Ruiqian Lin

{"title":"Correlation of Serum High-Sensitivity C-Reactive Protein, Homocysteine, and Macrophage Migration Inhibitory Factor Levels With Symptom Severity and Cognitive Function in Patients With Schizophrenia.","authors":"Saizheng Weng, Rongyan Zheng, Ruiqian Lin","doi":"10.1097/WNF.0000000000000594","DOIUrl":"10.1097/WNF.0000000000000594","url":null,"abstract":"Objective: This trial analyzed high-sensitivity C-reactive protein (hs-CRP), homocysteine (Hcy), and macrophage migration inhibitory factor (MIF) level in serum and their correlation with symptom severity and cognitive function in patients with schizophrenia (SP).Methods: Sixty-eight SP patients were enrolled in the SP group, and 68 healthy volunteers were in the control (CN) group. Serum hs-CRP, Hcy, and MIF were measured, and symptom severity was assessed with the Positive and Negative Symptom Scale (PANSS). Cognitive function was determined with the MATRICS Consensus Cognitive Battery (MCCB). The SP group was divided into high PANSS score (PANSS ≥70 points) and low PANSS score (PANSS <70 points), or the mild cognitive dysfunction group and severe cognitive dysfunction group according to the median MCCB score. The correlation between serum hs-CRP, Hcy, and MIF levels and PANSS and MCCB scores in SP patients was examined by Pearson correlation analysis.Results: SP patients had higher serum hs-CRP, Hcy, and MIF levels and showed higher PANSS scores and lower MCCB total score. Serum hs-CRP, Hcy, and MIF levels in the high PANSS group were higher than those in the low PANSS group and in the severe cognitive dysfunction group than in the mild cognitive dysfunction group. Serum hs-CRP, Hcy, and MIF levels in SP patients were positively correlated with PANSS total score and negatively correlated with MCCB total score.Conclusion: High serum hs-CRP, Hcy, and MIF levels in SP patients are correlated with symptom severity and cognitive dysfunction.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"82-86"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Emergency Department and Psychiatric Boarding: A Model for the Future. 急诊室和精神病院寄宿：未来的模式。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000595

David R Spiegel

引用次数: 0

Metronidazole-Induced Encephalopathy With Probable Crohn Encephalitis: A Case Report. 甲硝唑诱发脑病，可能伴有克罗恩脑炎：病例报告。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000592

Raymond Klevor, Mariama Jarti, Mohamed Chraa, Nissrine Louhab, Khadija Krati, Najib Kissani

{"title":"Metronidazole-Induced Encephalopathy With Probable Crohn Encephalitis: A Case Report.","authors":"Raymond Klevor, Mariama Jarti, Mohamed Chraa, Nissrine Louhab, Khadija Krati, Najib Kissani","doi":"10.1097/WNF.0000000000000592","DOIUrl":"10.1097/WNF.0000000000000592","url":null,"abstract":"Objectives: Metronidazole central nervous system toxicity is a rare finding in patients receiving the medication. We report a peculiar case of metronidazole central nervous system toxicity in which both the underlying condition (Crohn disease) and the drugs used to treat it are potential causes of encephalopathy.Methods: A 26-year-old female with 6-year history of Crohn's disease for 6 years presented acute-onset encephalopathy. We provide bibliographic evidence to support metronidazole toxicity and potential Crohn disease-associated neurologic involvement.Results: The patient presented dystonia, cerebellar ataxia, and altered mental status. Magnetic resonance imaging of the brain revealed typical findings of metronidazole toxicity and white matter involvement of the centrum semiovale. Immunoelectrophoresis and immunofixation of serum and cerebrospinal fluid proteins were consistent with a systemic inflammatory process. We concluded on an association between drug toxicity and probable Crohn-associated neurologic involvement. Metronidazole was stopped and the patient was placed on vitamin therapy and diazepam to control dystonia. She deteriorated and was transferred to the intensive care unit where she expired.Conclusions: Acute behavioral changes in a young patient constitute an emergency and differential diagnoses should include infective, inflammatory, metabolic, and toxic causes. Metronidazole is a potential toxic etiology.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"104-107"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 用于偏头痛急性期治疗的 Zavegepant：随机对照试验的系统回顾和元分析》。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI: 10.1097/WNF.0000000000000588

Vinay Suresh, Mainak Bardhan, Tirth Dave, Muhammad Aaqib Shamim, Dilip Suresh, Poorvikha Satish, Bishal Dhakal, Aman Bhonsale, Priyanka Roy, Bijaya Kumar Padhi, Teshamae Monteith

{"title":"Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Vinay Suresh, Mainak Bardhan, Tirth Dave, Muhammad Aaqib Shamim, Dilip Suresh, Poorvikha Satish, Bishal Dhakal, Aman Bhonsale, Priyanka Roy, Bijaya Kumar Padhi, Teshamae Monteith","doi":"10.1097/WNF.0000000000000588","DOIUrl":"10.1097/WNF.0000000000000588","url":null,"abstract":"Objective: Evaluate the safety and efficacy of zavegepant (BHV-3500), a recently approved nasal spray containing a third-generation calcitonin gene-related peptide receptor antagonist, for treating acute migraine attacks.Methods: A comprehensive search was conducted across various databases up to 06/26/2023 to identify relevant randomized clinical trials (RCTs) on zavegepant's efficacy and safety in treatment of acute migraine attacks. Primary outcome: freedom from pain at 2 hours postdose. Safety outcomes were evaluated based on adverse events (AEs), with zavegepant 10 mg and placebo groups compared for incidence of AEs.Results: Two RCTs, involving 2061 participants (1014 receiving zavegepant and 1047 receiving placebo), were quantitatively analyzed. An additional trial was included for qualitative synthesis. Zavegepant 10 mg exhibited a significantly higher likelihood of achieving freedom from pain at 2 hours postdose compared with the placebo group (risk ratio [RR] 1.54, 95% confidence interval [CI] 1.28 to 1.84). It also showed superior relief from the most bothersome symptoms at 2 hours postdose compared with placebo (RR 1.26, 95% CI 1.13 to 1.42). However, the zavegepant 10 mg group experienced a higher incidence of AEs compared with placebo (RR 1.78, 95% CI 1.5 to 2.12), with dysgeusia being the most reported AE (RR 4.18, 95% CI 3.05 to 5.72).Conclusion: Zavegepant 10 mg is more effective than placebo in treating acute migraine attacks, providing compelling evidence of its efficacy in relieving migraine pain and most bothersome associated symptoms. Further trials are necessary to confirm its efficacy, tolerability, and safety in diverse clinic-based settings with varied patient populations.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"72-81"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0